Clearside Biomedical, Inc. (CLSD)
NASDAQ: CLSD · Real-Time Price · USD
3.900
+0.020 (0.52%)
Oct 28, 2025, 4:00 PM EDT - Market closed
Clearside Biomedical Revenue
Clearside Biomedical had revenue of $492.00K in the quarter ending June 30, 2025, with 446.67% growth. This brings the company's revenue in the last twelve months to $4.17M, down -44.63% year-over-year. In the year 2024, Clearside Biomedical had annual revenue of $1.66M, down -79.77%.
Revenue (ttm)
$4.17M
Revenue Growth
-44.63%
P/S Ratio
4.74
Revenue / Employee
$130,188
Employees
32
Market Cap
20.41M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.66M | -6.56M | -79.77% |
| Dec 31, 2023 | 8.23M | 6.90M | 519.89% |
| Dec 31, 2022 | 1.33M | -28.25M | -95.51% |
| Dec 31, 2021 | 29.58M | 21.68M | 274.65% |
| Dec 31, 2020 | 7.89M | 5.72M | 263.28% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
CLSD News
- 2 months ago - Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress - GlobeNewsWire
- 3 months ago - Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada - GlobeNewsWire
- 3 months ago - Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline - GlobeNewsWire
- 4 months ago - Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting - GlobeNewsWire
- 5 months ago - Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum - GlobeNewsWire
- 5 months ago - Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting - GlobeNewsWire
- 6 months ago - Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025 - GlobeNewsWire